NCT05627947

Comparison Between Topical Mitomycin C and Cyclosporine

Comparison Between Topical Mitomycin C and Cyclosporine After Primary Pterygium Surgery

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Egymedicalpedia · Industry
• Sex: All
• Age: 45 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.

Detailed description

The first line of treatment for primary pterygium is surgical excision, and despite postoperative adjuvant therapy using mitomycin C, cyclosporine, β-irradiation, argon laser, and bevacizumab, recurrence rates remain high . Mitomycin C is a metabolic inhibitor extracted from Streptomyces caespitosus that inhibits DNA synthesis . Cyclosporine is an immunosuppressant that selectively suppresses T-helper cells, controls interleukin synthesis and secretion, and inhibits vascular endothelial growth factor (VEGF) Bevacizumab is an anti-VEGF antibody that inhibits angiogenesis. Each agent has been studied as an adjuvant therapy to inhibit post-surgery pterygium recurrence.

Conditions

• Pterygium

Interventions

Type	Name	Description
DRUG	Mitomycin c	Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery

Timeline

• Start date: 2021-01-01
• Primary completion: 2022-06-15
• Completion: 2022-06-30
• First posted: 2022-11-28
• Last updated: 2023-10-17

Locations

1 site across 1 country: Egypt